Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash from Financing Activities (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Cash from Financing Activities for 6 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 5.36% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.8 million, a 71.17% decrease, with the full-year FY2025 number at $4.8 million, down 71.17% from a year prior.
  • Cash from Financing Activities was $4.1 million for Q4 2025 at Caribou Biosciences, up from $277000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $322.7 million in Q3 2021 to a low of -$43000.0 in Q4 2023.
  • A 5-year average of $30.6 million and a median of $630000.0 in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 288009.82% in 2021, then crashed 133.86% in 2023.
  • Caribou Biosciences' Cash from Financing Activities stood at $460000.0 in 2021, then tumbled by 72.39% to $127000.0 in 2022, then tumbled by 133.86% to -$43000.0 in 2023, then soared by 9083.72% to $3.9 million in 2024, then increased by 5.36% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Cash from Financing Activities are $4.1 million (Q4 2025), $277000.0 (Q3 2025), and $6000.0 (Q2 2025).